NCT04254107
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease; Patients with prior exposure to any anti-TIGIT monoclonal antibody; For Part C, patients with previous therapy of an anti-PD-1 or anti-PD-L1 inhibitor (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab)
https://ClinicalTrials.gov/show/NCT04254107